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Potential strategies to normalize the levels of homocysteine ENHANCEMENT OF HCY REMETHYLATION
in chronic renal failure patients. Recently published evidence BY FOLATE THERAPY
suggests that, either than folate therapy, the enhancement of
Folate plays an essential role in the remethylation path-homocysteine remethylation in tissues by correcting the multi-
ple abnormalities of the remethylation pathway in chronic renal way via its active metabolite 5-methyltetrahydrofolate
failure that extend beyond folate-related disturbances, or else (MTHF) (Fig. 1). Relative resistance to folate action is
the improved removal of uremic toxins and/or Hcy through present in CRF patients [5]. Indeed, routine minimalintensified dialysis procedures may represent two strategies to
folic acid supplementation of 1 mg daily, in contrast tonormalize total homocysteine in uremic patients.
what has generally been observed in the population at
large, does not have an effect on plasma total Hcy con-
centration in CRF patients, despite a supranormal plasmaA moderate elevation of plasma total homocysteine
folate level [5]. Even worse, the oral supplementation(Hcy) concentration is present in the early stage of chronic
renal failure (CRF), increases to parallel the degree of with high doses of folic acid (up to 15 mg daily), which
reduction in renal function, and persists after starting leads to a 20- to 50-fold increase of plasma folate concen-
dialysis treatment [1]. In view of the potential athero- trations, is only partially effective in reducing plasma
thrombogenic role of hyperhomocysteinemia, attempts total Hcy, and few dialysis patients normalize their Hcy
have been made to lower plasma total Hcy concentra- concentrations entirely [1]. Active reduced forms of folic
tions in CRF patients. However, Hcy-lowering therapies acid also do not lead to a greater decrease in fasting
in CRF patients have been shown to reduce, not to nor- plasma total Hcy levels than those observed with native
malize, plasma total Hcy concentrations, particularly in folic acid supplementation in hemodialysis patients [6–9].
dialysis patients [1]. The main reason for the reduced These data suggest that the initial hypothesis claiming
efficacy of Hcy-lowering therapies is unclear at present. the presence of abnormal folate metabolism in these pa-
It probably is related to our still limited understanding tients was incorrect [10]. They are in line with data pub-
of the etiology of hyperhomocysteinemia in CRF pa- lished by Bostom et al [6] of normal folate metabolism,
tients. A reduction of plasma Hcy clearance has been as assessed by normal baseline plasma 5-MTHF levelsdemonstrated in the uremic state [2], but whether it
and a significant increase in total plasma folate, predomi-results from reduced Hcy renal clearance, from an im-
nantly plasma 5-MTHF, after oral treatment with eitherpairment of the extra-renal clearance by the presence of
folic acid or L-5-MTHF patients. Of note, folic acid sup-uremic toxins, or a combination of these factors remains
plementation did not enhance the impaired Hcy clear-to be clarified. Genetic- and dialysis-related factors may
ance in six CRF patients, even though it lowered totalalso participate in the pathogenesis of this type of hyper-
Hcy levels [2]. One recent interpretation of these findingshomocysteinemia [1]. It is noteworthy that an alteration
is that folic acid enhances the remethylation of Hcy inof the remethylation pathway, but not of the transsul-
the tissues and lowers its efflux into the plasma compart-furation pathway, has been demonstrated in hemodialy-
sis patients [3], underlining the importance of Hcy re- ment; however, this could not be sufficient enough to
methylation in such patients. Of note, in the rat kidney, override the primary defect in Hcy metabolism (i.e., the
the majority of Hcy seems to degrade via the transsul- reduction of Hcy clearance from plasma), or to obtain
furation pathway [4]. In this review, we shall outline normal steady state levels in dialysis patients [11]. There-
potential strategies (intervention therapies and/or dial- fore, either the enhancement of tissue Hcy remethylation
ysis modalities) used in order to improve Hcy lowering by correcting possible remethylation pathway abnormal-
in CRF patients. ities beyond folate-related disturbances, or the improve-
ment of uremic toxin and/or Hcy removal through inten-
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strategies to normalize total Hcy in CRF patients. 2003 by the International Society of Nephrology
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Table 1. Possible remethylation pathway abnormalities beyond
folate-related disturbances in chronic renal failure patients
Relative resistance to vitamin B12 action
Relative resistance to vitamin B6 action
Vitamin B2 deficiency
Reduction of betaine-homocysteine methyl transferase activity
ously attained by using high-dose folic acid and pyridox-
ine. This latter study underlines the fact that only phar-
macologic tissue concentrations of cobalamin can fully
overcome the resistance to vitamin B12 action present in
CRF patients.
The reduction of betaine-homocysteine methyl trans-
ferase activity, which is probably due to an accumulation
of dimethylglycine in the plasma of uremic patients, may
contribute to hyperhomocysteinemia [12]. Betaine-homo-
cysteine methyl transferase regulates the alternative re-
methylation pathway in the liver and renal cortex by
transferring a methyl group from glycine-betaine to ho-
mocysteine, producing methionine and dimethylglycine
(Fig. 1). It should be noted, however, that glycine-betaine
supplementation had no effect on fasting total Hcy in
CRF patients [16].
Not only does vitamin B6 play a key role as coenzyme
in the transsulfuration pathway, but also as coenzyme
for serine hydroxymethyltranseferase (SMHT) (Fig. 1)Fig. 1. Overview of homocysteine metabolism with particular empha-
sizing of the remethylation pathways: the remethylation pathway by [17]. SMHT is responsible for the conversion of tetrahy-
methionine synthase, and an alternative remethylation pathway by beta- drofolate (THF) to 5,10-methylene-THF (Fig. 1) [17]. Aine-homocysteine methyl transferase. Abbreviations are: Ado, adeno-
portion of the 5,10-methylene-THF is transformed bysyl; Hcy, homocysteine; DHF, dyhydrofolate; THF, tetrahydrofolate;
MTHF, methyltetrahydrofolate; METHF, methylene tetrahydrofolate; 5,10-methylene-THF reductase to 5-MTHF, which serves
SHM, serine hydromethyl; B2, vitamin B2 (riboflavin); B3, vitamin B3 as methyl donor for homocysteine remethylation to me-
(niacin); B6, vitamin B6 (pyridoxine); B12, vitamin B12. thionine. In rats, vitamin B6 deficiency has been shown
to substantially affect both methyl group production for
homocysteine remethylation, and flux through whole-ENHANCEMENT OF HCY REMETHYLATION
body transulfuration [18]. Relative resistance to vitamin
BEYOND FOLATE ADMINISTRATION B6 action is also present in CRF patients [5]. It does not
Multiple abnormalities of the remethylation pathway seem to be caused by poor absorption or low tissue
that are not related to folate have been observed in stores, but rather by nonvitamin factors or potentially
CRF patients (Table 1) [5, 12, 13]. These abnormalities high levels of toxic pyridoxic acid (an end product of
may also participate in the genesis of hyperhomocys- vitamin B6 metabolism) in CRF patients [19].
teinemia in CRF patients. Vitamin B12 is one factor of
the remethylation pathway (Fig. 1), and a relative resis-
IMPROVEMENT OF REMOVAL OF UREMICtance to its action is also present in CRF patients [5]. In
TOXINS AND/OR HCYa recent study, Manns et al [14] demonstrated that the
supplementation of oral vitamin B12 (1 mg/day) to hemo- In patients with CRF who are not yet on dialysis, folate
dialysis patients who were not vitamin B12–deficient by treatment normalizes total Hcy levels, in contrast to the
usual laboratory standards, and who were receiving 1 mg large majority of dialysis patients, who generally retain
folic acid per day, lowered tHcy levels by an additional a substantial degree of residual hyperhomocysteinemia
16.7% compared with folic acid alone. More interest- [1]. The accumulation of uremic toxins and the decrease
ingly, Elian et al [15] found that administering a pharma- in Hcy clearance, and metabolism owing to a decreased
cologic dose (1 mg/wk parenterally) of hydroxycobalamin functioning renal mass are the two possible explanations
to vitamin B12-replete hemodialysis patients receiving 5 for the reduced efficacy of folate therapy. Therefore, a
to 6 mg/day of folic acid and 5 to 10 mg/day of pyridoxine more efficient dialysis procedure could lead to an im-
increased their average serum vitamin B12 concentration provement of the removal of uremic toxins and/or Hcy.
60-fold and reduced their average plasma total Hcy con- Standard dialysis procedures using low-flux dialyzers
have been unable to remove sufficient amounts of Hcycentration 32% below the lowest level that was previ-
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